On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome
about
Prospects for Improving Brain Function in Individuals with Down SyndromePharmacological interventions for cognitive decline in people with Down syndromeNeurological phenotypes for Down syndrome across the life spanDigastric Muscle Phenotypes of the Ts65Dn Mouse Model of Down SyndromeGlobal DNA hypermethylation in down syndrome placentaExaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantineA new cognitive evaluation battery for Down syndrome and its relevance for clinical trialsAge-related neurodegeneration and memory loss in down syndrome.From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial.Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome.An update of childhood genetic disorders.Down syndrome: Cognitive and behavioral functioning across the lifespan.SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature.Cardiac autonomic modulation of children with Down syndrome.Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.Reduced cortical neurotransmitter receptor complex levels in fetal Down syndrome brain.Alzheimer disease: Treatment of Alzheimer disease in Down syndrome.
P2860
Q22252566-86FE6285-9C46-43D6-AB1D-A9219C912AF6Q24186316-D4879B2A-DE27-40B2-9D6F-AE806E1DFE60Q27025698-BDC01721-ED62-46A4-B7F6-592D49B546DFQ28552115-0E670554-116E-4DEB-8563-1EA7693BE021Q34765333-2B445F39-9B1F-4E77-B25D-CAC3E7A6BD84Q35569636-0AEF71F7-BECF-4831-A60C-A1B4176F7131Q35682486-A4CDBCCE-53F6-41BA-BFD2-D6F7254520F0Q35867093-B005643B-5979-4EDA-977A-59C505F4DFB8Q36111747-B8838340-38DE-484E-9377-E1332B48BAD3Q36137301-F56FC69D-1373-487C-8DD2-A08E93568912Q37734742-0BD77490-4768-4E57-97B1-175896A5137DQ38072145-C439BFC7-A33C-4E82-BB70-DD0861D80D13Q38491559-6CCA9987-FAD1-4171-86E0-D4D953FD48C1Q38904944-4CFB1461-70E6-44F2-A7B9-9D48300E9EC6Q44951645-D8BF7EFC-A0B5-49F7-A612-C8A74B86156BQ46652242-AF6C2132-9E45-4385-A288-C717F4EC181DQ50211157-1E990C65-4C74-430C-B87F-0F5691AB9B18Q50962404-A6A3750A-CEA1-4E33-BB0B-9D2A561F39D3
P2860
On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
On the promise of pharmacother ...... ve components of Down syndrome
@ast
On the promise of pharmacother ...... ve components of Down syndrome
@en
On the promise of pharmacother ...... ve components of Down syndrome
@en-gb
On the promise of pharmacother ...... ve components of Down syndrome
@nl
type
label
On the promise of pharmacother ...... ve components of Down syndrome
@ast
On the promise of pharmacother ...... ve components of Down syndrome
@en
On the promise of pharmacother ...... ve components of Down syndrome
@en-gb
On the promise of pharmacother ...... ve components of Down syndrome
@nl
prefLabel
On the promise of pharmacother ...... ve components of Down syndrome
@ast
On the promise of pharmacother ...... ve components of Down syndrome
@en
On the promise of pharmacother ...... ve components of Down syndrome
@en-gb
On the promise of pharmacother ...... ve components of Down syndrome
@nl
P2860
P921
P3181
P356
P1476
On the promise of pharmacother ...... ve components of Down syndrome
@en
P2093
Alberto C S Costa
P2860
P304
P3181
P356
10.1159/000330861
P407
P577
2011-09-02T00:00:00Z